Clinical Trials

Live Rotavirus Vaccine 89% Effective - And Safe, Too

Published in Vaccine Weekly, August 16th, 1999

A new live rotavirus vaccine appears far more effective - and at least as safe - as the currently approved vaccine.

Results of a U.S. Phase II, multicenter, randomized, placebo-controlled clinical trial indicated that after two doses the live attenuated human rotavirus vaccine - dubbed 89-12 - was 89 percent effective with a 95% confidence interval (CI) of 65.4-94.5 percent.

The current reassortant tetravalent vaccine, based on rhesus rotavirus, after three doses is 49 to 68 percent effective in developed countries.

"The efficacy reported in this study (89 percent against any rotavirus illness) is the highest reported for any...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry